|
Aug 12
|
Belite Bio Inc (BLTE) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses
|
|
Aug 11
|
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
|
|
Aug 7
|
Belite Bio Announces Registered Direct Offering of $15 Million
|
|
Aug 6
|
Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference
|
|
Aug 4
|
Belite Bio to Host Webcast on August 11, 2025, to Discuss Second Quarter 2025 Financial Results
|
|
Jul 27
|
A Look At The Intrinsic Value Of Belite Bio, Inc (NASDAQ:BLTE)
|
|
Jul 23
|
Belite Bio to Participate in the BTIG Virtual Biotechnology Conference
|
|
Jul 2
|
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
|
|
Jan 21
|
Breakeven On The Horizon For Belite Bio, Inc (NASDAQ:BLTE)
|
|
Sep 26
|
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
|
|
Jun 12
|
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
|
|
May 14
|
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
|
|
May 14
|
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 13
|
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
|
|
Jan 9
|
Is There An Opportunity With Belite Bio, Inc's (NASDAQ:BLTE) 49% Undervaluation?
|
|
Nov 30
|
Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
|
|
Nov 7
|
Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results
|
|
Nov 6
|
Belite Bio, Inc. to present at the Deutsche Bank ADR Virtual Investor Conference on 8 November 2023
|
|
Nov 6
|
Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting
|
|
Apr 25
|
Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting
|